BGB A3055
Alternative Names: BGB-A3055Latest Information Update: 14 Oct 2025
At a glance
- Originator BeiGene
 - Developer BeOne Medicines
 - Class Antineoplastics; Monoclonal antibodies
 - Mechanism of Action CCR8 receptor antagonists
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Phase I Solid tumours
 
Most Recent Events
- 14 Oct 2025 BGB A3055 is still in phase I trials for Solid tumours (Combination therapy, Late stage disease, Metastatic disease, Second line therapy or greater) in Australia, US, China, France and South Korea (IV)
 - 14 Oct 2025 BGB A3055 is still in phase I trials for Solid tumours (Monotherapy, Late stage disease, Metastatic disease, Second line therapy or greater) in Australia, US, China, France and South Korea (IV)
 - 25 Apr 2025 Pharmacodynamics data from preclinical studies in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)